Welcome to our dedicated page for Modular Med SEC filings (Ticker: MODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Modular Medical, Inc. (Nasdaq: MODD) files a range of reports and disclosures with the U.S. Securities and Exchange Commission (SEC) that document its activities as a development-stage medical device company focused on insulin delivery technology. This page aggregates those SEC filings and pairs them with AI-powered summaries to help readers understand the key points in each document.
For Modular Medical, current reports on Form 8-K are especially relevant. The company has used 8-K filings to describe material definitive agreements for underwritten public offerings of common stock and accompanying warrants, warrant inducement arrangements, and related gross proceeds. These filings also outline terms such as exercise prices, warrant durations, over-allotment options, and underwriter compensation. Other 8-Ks disclose Nasdaq notices regarding the company’s compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, including the time periods granted to regain compliance.
Registration statements on Form S-3 and other referenced registration statements are important for understanding how Modular Medical registers shares underlying warrants and other securities issued in its financings. Filings also confirm the company’s incorporation in Nevada and its status as a development-stage medical device company, as well as providing context for its capital structure.
On this page, AI-generated overviews highlight the main elements of each filing, such as new financing transactions, warrant terms, listing compliance developments, and references to the company’s insulin delivery technology focus. Users can quickly identify which documents address topics like public offerings, private placements, or Nasdaq communications, while still having access to the full text of the official SEC filings for detailed review.
Modular Medical, Inc. (Nasdaq: MODD) has filed its Form 10-K for the fiscal year ended March 31, 2025. The filing confirms that the Nevada-incorporated diabetes-focused medical device company remains a non-accelerated filer, smaller reporting company, and is not an emerging growth company. The report was filed on a timely basis and the registrant affirms that all required reports and interactive data files have been submitted during the preceding 12 months.
Capital structure and market data: as of June 16, 2025, the company had 54,247,388 shares of common stock outstanding. The aggregate market value of shares held by non-affiliates was $62.27 million based on the September 30, 2024 Nasdaq closing price.
The 10-K outlines a full set of standard disclosures, including risk factors (Item 1A), management’s discussion & analysis (Item 7), and financial statements (Item 8), but detailed revenue, earnings and cash-flow figures are not included in the excerpt provided. A lengthy Special Note Regarding Forward-Looking Statements lists more than a dozen risk considerations, mainly centred on:
- Obtaining FDA clearances for its insulin pump products.
- Financing needs and liquidity horizon.
- Competition from larger diabetes device manufacturers.
- Protection of intellectual property.
- Ability to hire and retain key personnel.
The company confirms it is not a shell company and that no restatement-triggering error corrections were included in the financials. No attestations under SOX 404(b) were provided, consistent with non-accelerated filer status.
Overall, the filing is largely procedural and centres on forward-looking risk disclosures rather than new financial performance metrics or strategic transactions.
FAQ
What is the current stock price of Modular Med (MODD)?
What is the market cap of Modular Med (MODD)?
